Comparing the outcomes between TMLI and non-TMLI conditioning regimens for adult high-risk acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a single-center experience

Comparing the outcomes between TMLI and non-TMLI conditioning regimens for adult high-risk acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a single-center experience
复制标题

成人高危急性淋巴细胞白血病患者接受异基因造血干细胞移植的 TMLI 和非 TMLI 预处理方案的结果比较:单中心经验

DOI:
10.1080/10428194.2020.1789621
复制
发表时间:
2020-07
期刊:
Leuk Lymphoma
影响因子:
--
通讯作者:
Wang HF
Wang HF
中科院分区:
其他
文献类型:
--
作者:
Zhao XY;Lu X;Tang L;Yan H;Chen W;Shi W;Zhong ZD;You Y;Xia LH;Hu Y;Wang HF

文献摘要

参考文献

相似文献

摘要本研究旨在回顾性评价成人高危急性淋巴细胞白血病(ALL)患者接受异基因造血干细胞移植(allo-HSCT)后的疗效。70例接受异基因造血干细胞移植的高危ALL成人患者,根据预适应方案分为两组(TMLI组:N = 29例,非TMLI组:N = 41例)。我们注意到在1年内估计的累积复发率(25%比46.5%,p = 0.018)、1年估计总存活率(73.1%比52.6%,p = 0.033)和无病存活率(65.2%比48.2%,p = 0.026)方面有显著的统计学差异,但在移植相关死亡率(12%比13.4%,p = 0.619)方面没有发现显著差异。对于接受allo-HSCT的高危ALL患者来说,含有TMLI的方案是安全和替代的。
Abstract This study aimed to retrospectively evaluate the outcomes of adult patients with high-risk acute lymphoblastic leukemia (ALL) who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) with either total marrow and lymphoid irradiation (TMLI)-containing or non-TMLI conditioning regimen. Seventy adult patients with high-risk ALL who received allo-HSCT were enrolled in this study and divided into two groups based on the conditioning regimen type (TMLI group: n = 29 and non-TMLI group: n = 41). We noted significant statistical differences in the 1-year estimated cumulative incidence of relapse (25% vs. 46.5%, p = 0.018), the 1-year estimated overall survival (73.1% vs. 52.6%, p = 0.033) and disease-free survival (65.2% vs. 48.2%, p = 0.026) but found no considerable difference in transplant-related mortality (12% vs. 13.4%, p = 0.619) between patients in the TMLI and non-TMLI groups. The TMLI-containing regimen is safe and alternative for patients with high-risk ALL undergoing allo-HSCT.
DOI: 10.1016/j.clml.2019.03.007
发表时间: 2019-07-01
影响因子: 2.7
作者:
Pasvolsky, Oren;Morelli, Olga;Raanani, Pia
通讯作者: Raanani, Pia
DOI: 10.1002/ajh.23109
发表时间: 2012-04-01
影响因子: 12.8
作者:
Mori, Takehiko;Aisa, Yoshinobu;Okamoto, Shinichiro
通讯作者: Okamoto, Shinichiro
DOI: 10.1186/s13014-018-1201-0
发表时间: 2018-12-17
期刊: RADIATION ONCOLOGY
影响因子: 3.6
作者:
Bao, Zhirong;Zhao, Hongli;Liu, Hui
通讯作者: Liu, Hui
DOI: 10.1016/j.bbmt.2005.10.026
发表时间: 2006-03-01
影响因子: 4.3
作者:
Wong, JYC;Liu, A;Somlo, G
通讯作者: Somlo, G
DOI: 10.1200/jco.1996.14.2.579
发表时间: 1996-02-01
影响因子: 45.3
作者:
Miralbell, R;Bieri, S;Chapuis, B
通讯作者: Chapuis, B